DELCF News and Press, Delic Holdings From 02/11/22

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28 Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystem The laboratory focuses on extraction optim...

Delic Holdings (CSE: DELC) (OTCQB: DELCF) , the leading psychedelic wellness platform, has sought to capitalize on the ongoing transformation within the mental health sector. The company is positioning itself as the United States’ leading psychedelic wellness platform committed to br...

Psychedelics sometimes cause bad trips by creating horrible scenarios for some individuals. Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (“MAPS”), recently talked about difficult trips and how people could be guided through these exp...

Legislators in the state of Oregon have introduced a bicameral initiative that will establish a 15-member group that will focus on psilocybin health equity. The task force will be made up of representatives of the indigenous community, individuals with experience with psychedelic treatment...

Tens of millions of Americans live in areas where mental health providers are scarce  Delic is working on making psychedelic-based treatments more accessible and affordable In 2021, the company acquired Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers...

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) , a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, will give a presentation on “Artificial Intelligence for Craft Cannabis Prod...

DELIC Labs President and CSO Dr. Markus Roggen to Speak at Emerald Conference Canada NewsWire Dr. Roggen to Address the "Artificial Intelligence for Craft Cannabis Products," Monday Feb 28, 2022, at 12:45pm PT VANCOUVER, BC , Feb. 3, 2022 /CNW/ - ...

A new study conducted by researchers at the Institute of Psychiatry, Psychology & Neuroscience has found that psilocybin can be administered safely to six participants at the same time, at doses of either 25 mg or 10 mg. Psilocybin is a naturally occurring hallucinogenic compound found...

Recently, psychotherapist training for a psychedelic clinical trial that is being led by Beckley Psytech began. This comes as interest in psychedelic substances and the properties and benefits they possess increases in America as well as the United Kingdom. Beckley Psytech specializes in...

Representative Brady Brammer recently filed a measure that would establish a task force to investigate whether psychedelic substances should be used as a treatment option for post-traumatic stress disorder and other mental health conditions. In an interview last week, the Utah representative...